Antengene Corporation Limited (6996) AI Stock Analysis

• Market Cap: €3.43B
• Dividend Yield: N/A
• Average Volume (3M): 6.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 30.54%
• EPS Growth: 48.43%
• Country: HK
• Employees: 169
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 679,446,660
• 10 Day Avg. Volume: 8,545,850
• 30 Day Avg. Volume: 6,679,417
• PEG Ratio: 0.03
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 4.12
• P/FCF Ratio: -0.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.02
• Price Target Upside: -40.56% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 57 Neutral
• Price Target: HK$5.00 ▼(-1.57% Downside)

Antengene Corporation Limited's overall stock score is driven primarily by its strong technical momentum, despite significant financial performance concerns. The company's valuation remains a risk due to negative earnings. Investors should be cautious of its operational and cash flow challenges.

Antengene Corporation Limited Business Overview & Revenue Model

Company Description

Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. Its products in pre-clinical stage include ATG-037 (CD73 inhibitor) for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031 (CD24 antibody); ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 (LILRB antibody); and ATG-041, an Axl-Mer inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.

How the Company Makes Money

Antengene Corporation Limited generates revenue primarily through the commercialization of its proprietary drug products, which are developed internally or acquired through strategic partnerships. The company's revenue model includes direct sales of approved drugs to healthcare providers, hospitals, and clinics. Additionally, Antengene may engage in licensing agreements and collaborations with other pharmaceutical and biotechnology companies to co-develop or co-market products. These partnerships can provide milestone payments, royalties, and shared profits that contribute to the company's earnings. Antengene's focus on high-demand therapeutic areas, coupled with strategic alliances, supports its revenue growth and market expansion efforts.

Antengene Corporation Limited Financial Statement Overview

Summary

Antengene Corporation Limited shows strong revenue growth but faces significant profitability and cash flow challenges. Despite a strong equity position, ongoing operational losses and negative cash flows are concerning.

Income Statement

The company shows consistent revenue growth over the years, with a notable increase from 2023 to 2024. However, the profitability metrics are concerning as both EBIT and Net Income margins are significantly negative, indicating ongoing operational losses. The gross profit margin is relatively strong at approximately 80.65% in 2024, but the high negative net income margin of -347.28% suggests severe challenges in managing expenses relative to revenue.

Balance Sheet

The balance sheet presents a strong equity position with a high equity ratio of 63.28% in 2024, reflecting a solid asset base funded by equity rather than debt. The debt-to-equity ratio is low at 0.29, indicating limited leverage. However, the continuous high net losses have eroded stockholders' equity over time, posing a risk to financial stability.

Cash Flow

Cash flow figures indicate significant challenges, with consistently negative operating and free cash flows. The operating cash flow to net income ratio is undefined due to zero operating cash flow in 2024, highlighting inefficiencies in converting revenue to cash. The free cash flow has improved from a negative base, but remains a critical area of concern.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	91.95M	67.31M	160.13M	28.77M	0.00
Gross Profit	74.17M	55.01M	132.00M	24.19M	0.00
EBITDA	-348.82M	-550.31M	-866.06M	-614.32M	-501.94M
Net Income	-319.25M	-581.18M	-601.49M	-655.53M	-2.93B
Balance Sheet
Total Assets	1.34B	1.62B	2.14B	2.56B	3.19B
Cash, Cash Equivalents and Short-Term Investments	900.24M	1.19B	1.79B	2.37B	3.11B
Total Debt	249.44M	201.02M	57.95M	14.81M	10.92M
Total Liabilities	493.93M	471.20M	428.84M	163.29M	156.59M
Stockholders Equity	850.80M	1.15B	1.71B	2.39B	3.04B
Cash Flow
Free Cash Flow	-382.57M	-778.87M	-665.56M	-581.04M	-358.87M
Operating Cash Flow	-321.96M	-665.77M	-572.18M	-557.65M	-307.12M
Investing Cash Flow	345.24M	587.07M	-208.16M	-103.88M	-600.57M
Financing Cash Flow	45.17M	131.84M	-20.73M	-81.29M	2.79B

Antengene Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Positive. The current price of 5.08 is above the 20-day moving average (MA) of 4.62, above the 50-day MA of 3.93, and above the 200-day MA of 2.31, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 59.15 is Neutral, neither overbought nor oversold. The STOCH value of 55.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6996.

Antengene Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	71 Outperform	HK$1.92B	48.36	4.92%	―	38.48%	―
6996	57 Neutral	€3.43B	―	-31.66%	―	30.54%	48.43%
1672	53 Neutral	HK$11.51B	―	-13.97%	―	-97.81%	-117.20%
3681	52 Neutral	HK$4.01B	―	-75.64%	―	42.21%	29.52%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.36%	15.48%	-2.68%
2179	42 Neutral	HK$3.63B	―	-69.97%	―	―	3.30%
6978	37 Underperform	HK$2.13B	―	-228.99%	―	―	44.88%

Antengene Corporation Limited Corporate Events

Antengene’s XPOVIO® Gains Approval in China for Multiple Myeloma Treatment

Antengene Corporation Limited announced that the China National Medical Products Administration has approved XPOVIO® (selinexor) for the second-line treatment of multiple myeloma in adult patients who have received at least one prior therapy. This approval enhances Antengene’s market positioning in the treatment of hematologic malignancies and expands the availability of its innovative therapies in the Asia Pacific region, potentially benefiting stakeholders by offering a novel treatment option with a unique mechanism of action.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

Antengene Corporation Announces Change of Hong Kong Business Address

Antengene Corporation Limited, a company incorporated in the Cayman Islands, has announced a change in its principal place of business in Hong Kong. Effective July 14, 2025, the company’s new address will be Units A & B, 12th Floor, Tern Centre Tower 1, 237 Queen’s Road Central, Hong Kong. This move signifies a strategic shift in the company’s operations, potentially impacting its logistical and operational efficiencies in the region.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

Antengene Corporation Successfully Passes All Resolutions at AGM

Antengene Corporation Limited announced that all proposed resolutions at its Annual General Meeting held on June 13, 2025, were successfully passed. These resolutions included the approval of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates for share issuance and repurchase. The outcomes of the AGM reflect strong shareholder support and are likely to impact the company’s strategic direction and operational capabilities positively.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.